Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Comirnaty (COVID-19 mRNA vaccine by Quarter
Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — U.S. reported YoY (%) (%)
Pfizer Comirnaty (COVID-19 mRNA vaccine: -79.0% in Q2 2026.
Latest, Q2 2026
-79.0%
Period ended Jun 28, 2026
Change on a year earlier
–
History
16 quarters
Since Q1 2022
Sources
16
Documents cited below
Where the Q2 2026 figure comes from
“|| Comirnaty | 261 | 381 | (32%) | (34%) | 38 | 176 | (79%) | 223 | 205 | 9% | 4%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Comirnaty (COVID-19 mRNA vaccine (%), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/comirnaty-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.